Special Issue

State of the Art and Future Directions of Synthetic Biology-Armed Vaccine Development

Message from the Guest Editors

Synthetic biology provides novel approaches for rebuilding existing biological systems or redesigning new ones from scratch for various applications. Over time, the so-called “bottom-up” synthetic biology has expanded to many research subjects, including biology, chemistry, computational sciences, and engineering. The state-of-the-art concepts and strategies of synthetic biology can also activate and shape the future of vaccine development into the next generation. Thus, we would like to invite researchers worldwide to contribute to this Special Issue with recent advances in the vaccine/antibody production and mechanism study armed with rational designs from synthetic biology. We welcome high-quality mini-review and research articles with results from various host models aimed at either laboratory or industrial level. Articles on synthetic cell-based antigen display or drug delivery systems are also welcome.

Guest Editors

Dr. Jian Xu
School of Life Sciences, East China Normal University, Shanghai 200062, China

Dr. Jae Man Lee
Laboratory of Creative Science for Insect Industries, Kyushu University Graduate School of Bioresource and Bioenvironmental Sciences, Motooka 744, Nishi-ku, Fukuoka 819-0395, Japan

Deadline for manuscript submissions

closed (30 November 2023)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/129802

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/vaccines

MDPI

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).